Several drugmakers whose sales boomed on COVID-19 vaccines and related products in 2021 and 2022 have now been embroiled in a hangover…
McAlinden Research PartnersOctober 18, 2023
The FTC's settlement with Amgen and Horizon has cleared the way for the two companies to complete a $27.8 billion…
McAlinden Research PartnersSeptember 5, 2023
Some gauges indicate that foreign investment in China has sunken to 25-year lows recently. Beijing sees development of the country's biotechnology…
McAlinden Research PartnersAugust 15, 2023
Summary: Ongoing shortages of popular obesity-fighting drugs from Novo Nordisk represent the surging popularity of medication-based intervention as treatment. Though…
McAlinden Research PartnersJuly 25, 2023
New FDA guidance meant to steer clinical trials of psychedelic compounds will play a major role in the eventual approval…
McAlinden Research PartnersJuly 12, 2023
Johnson & Johnson's most recent earnings data showed revenues and earnings per share growing more robustly than analysts anticipated. However,…
McAlinden Research PartnersApril 18, 2023
A potential acquisition of Seagen by Pfizer, likely in the neighborhood of $40.0 billion, would be the biggest biopharma deal…
McAlinden Research PartnersFebruary 27, 2023
Throughout the past month, legislators in nearly half a dozen US states have introduced bills focused on reforming laws that…
McAlinden Research PartnersJanuary 30, 2023
Shares of biotechnology firms focused on gene editing were slammed this week by an FDA hold placed on Verve Therapeutics'…
McAlinden Research PartnersDecember 8, 2022
